Duncan Barbara Gayle

Duncan Barbara Gayle is listed in filings as Director at Halozyme Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 7, 2026, including 13 public disclosures. Recent filings connect the profile to Halozyme Therapeutics, Inc. (HALO), Ovid Therapeutics Inc. (OVID), and Atea Pharmaceuticals, Inc. (AVIR). The current snapshot covers public activity from Jun 18, 2024 to May 7, 2026. Reported amounts are shown as $397.9K to $133.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.